Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/18/22
End: 03/25/25
Due: 03/25/26
Phase: N/A
Priority: Normal
Start: 09/13/21
End: 03/30/26
Due: 03/30/27
Phase: N/A
Priority: Normal
Start: 05/11/23
End: 02/28/27
Due: 02/28/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| XTX202 in Patients With Advanced Solid Tumors | NCT05052268 | Xilio Development, Inc. | user2@example.com | None | 2022-01-18 | 2025-03-25 | 2026-03-25 | - | - | 2025-07-14 |
| Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | NCT04896697 | Xilio Development, Inc. | user2@example.com | None | 2021-09-13 | 2026-03-30 | 2027-03-30 | - | - | 2025-07-14 |
| XTX301 in Patients With Advanced Solid Tumors | NCT05684965 | Xilio Development, Inc. | user2@example.com | None | 2023-05-11 | 2027-02-28 | 2028-02-28 | - | - | 2025-07-14 |